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1

Introduction

2

Chronic hepatitis B (HBV) infection is a major cause of liver cirrhosis and cancer contributing

3

to a significant burden of disease worldwide[1]. Most cases of chronic infection are acquired

4

early in life, predominantly through maternal transmission[1]. Australia is considered to have

5

low HBV prevalence (<2%), however in Aboriginal and Torres Strait Islander (hereafter

6

referred to as Aboriginal) people[2], some migrant populations[3] and people who inject

7

drugs[4], HBV prevalence is substantially higher.

8

A vaccine which is 95% effective in preventing HBV has been available since 1982 and since

9

then, various HBV vaccination programs have been implemented across the States and

10

Territories of Australia[5]. Early recommendations were for at-risk adults, and infants and

11

young children from ethnic groups with high HBV carriage rates to be targeted for

12

vaccination[5]. In 1990 a universal neonatal hepatitis B vaccination program, where all babies

13

born were given a 3 dose schedule of HBV vaccine starting from birth, was implemented in

14

the Northern Territory (NT) a region where 28% of the population are Aboriginal (compared

15

with 3% nationally [6]). Subsequently, from May 2000, the HBV vaccine was included in

16

Australia’s national infant vaccination schedule, with all babies recommended to receive the

17

first dose at birth. In parallel with the national infant program, schools-based catch-up

18

programs were implemented at various grades and time periods across the Australian States

19

and Territories[5].

20

Screening pregnant women for HBV, and provision of post-exposure prophylaxis to babies

21

born to HBV-positive mothers remains an important element in prevention of transmission of

22

the virus. Since the late 1990s, screening for HBV with hepatitis B surface antigen (HBsAg)

23

has been recommended and conducted as part of routine care for all pregnant women in

24

Australia[7] with over 90% of pregnant women in WA reported as undergoing HBV screening

25

in 2002[8]. Thus, testing of birthing mothers in Australia provides an opportunity to represent

26

a sentinel population for monitoring chronic HBV prevalence and assessing the impact of HBV

27

prevention programs. Previous analyses using this methodology in two Australian

28

jurisdictions, the NT[2] and New South Wales (NSW)[9], reported decreases in the prevalence

29

of HBV among Aboriginal women giving birth following the introduction of targeted and

30

newborn vaccination programs. However, differences were observed in overall HBV

31

prevalence across the two jurisdictions among both Aboriginal (2.4% in the NT and 0.79% in

32

NSW), and non-Aboriginal women (0.04% in the NT and 0.11% in NSW).

33

To provide a more complete picture of the ongoing impact of the HBV vaccination programs,

34

and assess the need for additional programs to target high risk populations in Australia, we

35

assessed the impact of HBV vaccination programs in Western Australia (WA) on the
1

36

prevalence of HBV infection among mothers giving birth in the State and compared this with

37

the two earlier studies in the NT and NSW[2, 9].

38

Methods

39

Data linkage and study population

40

This study was conducted using population-based record linkage in Western Australia (WA)

41

(population 2.6 million)[10]. The WA Data Linkage Branch has created and maintained

42

probabilistic linkages between core health datasets using personal identifiers such as name,

43

date of birth, address, and sex. Linkage accuracy using this process is high with an error rate

44

estimated at 0.11%[11].

45

A cohort comprising all women in WA with year of birth between 1974-1995 was determined

46

by selecting any women appearing in either the WA Registry of Births (which contains all birth

47

registrations in WA from 1974 onwards) or the 2014 WA Electoral Commission enrolments

48

database. For women in this cohort, linked data was extracted from two health datasets. The

49

WA Midwives Notification System is a statutory database which receives information from birth

50

attendants about all births attended in the state of WA where the infant has a gestational age

51

of 20 weeks or more, a birthweight of 400g or more, or if gestational age is unknown. Data

52

reported for each birth include maternal year of birth, date of giving birth, maternal postcode

53

of residence, ethnicity and birth details such as parity. The WA Notifiable Infectious Diseases

54

Database contains a record of all notifiable conditions reported to the WA Department of

55

Health under statute including HBV. Both acute and non-acute (unspecified) infections

56

detected by laboratory testing are recorded according to strict case definitions[12] and the

57

date of notification is also recorded.

58

All women in the cohort resident in WA and who gave birth to their first child (i.e. parity null)

59

between 1st January 2000 and 31st December 2012, as determined from the Midwives

60

Notification System, were included.

61

Statistical analysis

62

A woman was defined as having chronic HBV infection at the time of delivery of her first child

63

if she had at least one linked notification of HBV prior to the birthing date. Women whose HBV

64

notification prior to birthing was classified as acute were excluded from the analysis.

65

The HBV prevalence in birthing women was calculated overall and stratified by Aboriginality

66

as determined from the Indigenous Status Flag created by the WA Data Linkage Branch[13].

67

HBV prevalence was then examined according to maternal year of birth classified into three

2

68

categories based on the likelihood of the mother being included in an HBV vaccination

69

program; (i) pre-HBV vaccine (1974-1981), (ii) HBV vaccine available and recommend for at-

70

risk adults (1982-1987), or (iii) targeted infant and school-based catch-up HBV vaccination

71

programs (1988-1995), (see Appendix for details). No women in our cohort were born during

72

the universal newborn vaccination program which commenced in May 2000. Chi-square tests

73

were used to examine trends in HBV prevalence across maternal birth year categories.

74

Logistic regression was used to investigate the association between maternal birth year

75

categories and HBV infection adjusted for other characteristics. These included area of

76

residence determined from the mother’s residential postcode reported in the Midwives

77

Notification System and classified as metropolitan, regional or remote according to the

78

Australian Standard Geographical Classification[14]; year of giving birth (per 5 year increase

79

from 2000 to 2012), maternal ethnicity for non-Aboriginal women (Caucasian, other).

80

Additional adjustments were made for maternal socioeconomic status based on maternal

81

postcode classified according to the index of relative socioeconomic disadvantage (high,

82

middle, low)[15], and maternal smoking (no, yes).

83

HBV prevalence in Aboriginal women by maternal year of birth was then compared between

84

the WA cohort, and published data from similar cohorts in the NT and NSW. All analyses were

85

performed using SAS version 9.4 (SAS Institute Inc, Cary, North Carolina).

86

Ethical approval

87

This study was approved by the Government of WA Department of Health Human Research

88

Ethics Committee (Ref #2012/73) and the WA Aboriginal Health Ethics Committee (Ref 470).

89
90

Results

91

A total of 66,086 women in the study cohort gave birth to their first child between 1st January

92

2000 and 31st December 2012 in WA. Thirteen women had a notification of acute HBV prior

93

to giving birth and were excluded leaving 66,073 women in the analysis. Of these women 7%

94

(4907) were Aboriginal, with a younger age at the time of giving birth compared to their non-

95

Aboriginal counterparts (mean age 19.1 years compared to 26.5 years, p<.0001) and a higher

96

proportion resident in regional or remote WA (64% vs. 22%, p<.0001).

97

Among the 66,073 women, 155 linked to a non-acute HBV notification dated prior to giving

98

birth giving an estimated prevalence of chronic HBV of 0.23%, 95%CI 0.20-0.27. Prevalence

99

was substantially higher in Aboriginal women (0.92%, 95%CI 0.65-1.18), than non-Aboriginal
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100

women (0.18%, 95%CI 0.15-0.21). As shown in Figure 1, among Aboriginal women, there was

101

a significant decreasing trend in prevalence of HBV with maternal year of birth (p for

102

trend<.0001). For those born in the pre-HBV vaccine era (year of birth 1974-1981) HBV

103

prevalence was 1.98% (95%CI 0.95-3.01); this fell progressively among those born in the era

104

of vaccination recommended for at-risk adults (1982-1987; 1.22%, 95%CI 0.74-1.69) and in

105

those born in the era that made them eligible for the targeted infant and school based catch-

106

up programs (1988-1995; 0.28%, 95%CI 0.10-0.61). Among non-Aboriginal women, the

107

decline in HBV prevalence across these 3 maternal birth year cohorts was not significant at

108

the 0.05 level (1974-1981: HBV prevalence 0.20% [0.16-0.25]; 1982-1987: 0.17% [0.11-0.23];

109

1988-1995: 0.08% [0.03-0.18]; ptrend=0.06).

110

In logistic regression analyses (Table 1), after adjusting for year of giving birth and region of

111

residence, Aboriginal women born in the two later periods (1982-1987 or 1988-1995) had

112

respectively, a 42% and 89% lower risk of HBV than Aboriginal mothers born between 1974-

113

1981 (adjusted odds ratio [aOR] respectively 0.58 [95%CI 0.30-1.13] and 0.11 [95%CI 0.04-

114

0.33]). Furthermore, Aboriginal women resident in regional and remote WA were three times

115

as likely to have a HBV notification compared to Aboriginal women resident in a major city

116

(aOR 3.06, 95%CI 1.1.36-6.88). These estimates were similar after additional adjustment for

117

maternal smoking and socioeconomic status.

118

Among non-Aboriginal women, after adjusting for year of giving birth, region of residence and

119

ethnicity, there was no significant difference in HBV prevalence across maternal birth year

120

categories (p=0.20), nor between those living in metropolitan regions and regional/remote

121

areas (p=0.23). However, among non-Aboriginal women, those identifying as non-Caucasian

122

had an estimated HBV prevalence of 1.6% compared to Caucasian women at 0.04%. After

123

adjustments, non-Caucasian women were more than 35 times as likely to have chronic HBV

124

than Caucasian women (aOR 36.08, 95%CI 22.66-57.46).

125

Comparing the data from WA Aboriginal women to that published from similar cohorts of

126

Aboriginal women giving birth in the NT[2] and NSW[9] we found comparable relative declines

127

in HBV prevalence according to maternal year of birth (Figure 2). However in absolute terms,

128

among women born from 1985 to 1990, HBV prevalence was about one percentage point less

129

among the WA women than in Aboriginal women in the NT, whilst HBV prevalence in WA

130

women was similar to that found in NSW Aboriginal women.

131
132

Discussion

4

133

This is the first study to report the prevalence of HBV among birthing mothers in WA and

134

examine differences between women born before and after the introduction of targeted HBV

135

vaccination programs. This study estimated the overall HBV prevalence in Aboriginal mothers

136

giving birth for the first time in WA during 2001-2012 to be 0.92%. In Aboriginal women, the

137

risk of HBV infection decreased by 89% in those eligible for at-risk infant and schools-based

138

catch-up vaccination programs compared to women born before the HBV vaccine was

139

available. Among non-Aboriginal women, the HBV prevalence was 0.18%, substantially lower

140

than in their Aboriginal counterparts and with no significant decline in prevalence observed

141

over the study period.

142

While this was an ecological study design, our results suggest that the targeted at-risk infant

143

and school-based HBV vaccination program has had a significant and long-lasting effect on

144

reducing chronic HBV in the WA Aboriginal population. However, our results also highlight that

145

continued monitoring is needed. Despite the declines in HBV observed in Aboriginal mothers,

146

even in the most recent maternal birth-cohort (1988-1995), the prevalence of HBV remained

147

higher in Aboriginal women compared to their non-Aboriginal counterparts (0.28% versus

148

0.08%). There were also substantial differences between Aboriginal women living in regional

149

and remote parts of the state with a 3-fold difference compared to Aboriginal women living in

150

cities. Furthermore, in non-Aboriginal women a 35-fold difference was observed between non-

151

Caucasian and Caucasian women.

152

This study used similar methodology as was used in two previous studies on the prevalence

153

of HBV in birthing mothers in Australia[2, 9]. Consistent across all three studies, was the

154

significant decline (~80%) in HBV prevalence among Aboriginal women associated with the

155

implementation of targeted vaccination programs in each of the jurisdictions (Figure 2). These

156

two earlier studies also noted that despite the large declines, HBV prevalence remained higher

157

in Aboriginal women compared to their non-Aboriginal counterparts of the same birth cohort,

158

and there were marked differences in HBV prevalence between Aboriginal women resident in

159

regional/remote areas compared to cities. While equivalent measures of ethnicity were not

160

available, the WA findings of a significantly higher HBV prevalence among non-Aboriginal

161

women comparing non-Caucasian to Caucasian also broadly mirrors findings in NSW, which

162

showed HBV prevalence of 1.95% among overseas-born women compared to 0.11% in non-

163

Aboriginal Australian-born women.

164

Despite the similarity in relative decline in HBV prevalence in Aboriginal women between the

165

three Australian jurisdictions that we compared, the absolute HBV prevalence in the NT

166

Aboriginal women was substantially higher than that in WA and NSW for all maternal birth

167

cohorts (Figure 2). According to standard geographic classifications[14], all of the population
5

168

in the NT would be classified as regional or remote. Therefore it is interesting that the

169

magnitude of the difference between HBV prevalence among women in similar birth cohorts

170

in WA and NT (eg: for Aboriginal women born around 1990 HBV prevalence in the NT was

171

almost three-times that in WA [0.28 versus 0.80], Figure 2) is about equivalent to that found

172

comparing women living in metropolitan to rural/remote regions of WA (aOR 3.06, Table 1). It

173

suggests geographic factors may underlie the higher prevalence found between jurisdictions

174

such as WA or NSW and the NT.

175

It is unclear why HBV prevalence in Aboriginal women is much higher among those born in

176

regional/remote areas than in metropolitan areas. Possible reasons include that similar to what

177

has been reported in some African countries,[16, 17] poorer housing and environmental

178

conditions in remote Aboriginal communities, with the associated greater crowding and

179

reduced skin hygiene, leads to higher horizontal transmission in such settings. It has also been

180

suggested that reduced access to health services in more remote populations[9] as well as

181

the potential for differences in circulating HBV genotypes between regions of Australia may

182

be contributing factors[18]. The differences in HBV prevalence in non-Aboriginal non-

183

Caucasian women compared to Caucasian women is almost certainly due to migrant

184

populations from high-HBV prevalence countries[3] however we did not have data on the

185

mothers’ country of birth to confirm this hypothesis.

186

Internationally, other studies assessing the long-term impact of infant and childhood HBV

187

vaccination program impact have reported greater reductions in HBV prevalence associated

188

with universal infant programs than with targeted programs; most assessments of universal

189

programs report reductions in HBV prevalence of 80% or greater [19, 20] whilst targeted (at-

190

risk) programs reported reductions ranging from 25-85%[19, 21]. Our WA findings relate only

191

to women exposed to targeted at-risk and school-based vaccination programs. Therefore, the

192

magnitude of the decline in HBV prevalence is in the upper range of that reported in other

193

studies and comparable to universal programs. While there are no data available on the WA

194

HBV vaccine program coverage during this early period, our results suggest it was very

195

successfully implemented and effective in reducing prevalence.

196

This study focuses on women giving birth in WA and the results may not be generalisable to

197

men or older women. In Australia[22] and internationally[17] men consistently have higher

198

HBV prevalence reported than women, although assuming that infant and early childhood

199

HBV vaccination programs are equally effective in boys, this difference is unlikely to affect the

200

relative reductions in prevalence estimated here. Also in the WA data, unlike in the earlier

201

NSW studies,[3] we lacked data on country of birth to disaggregate the very high HBV

202

prevalence in the non-Caucasian women according to this variable. Finally, in interpreting our
6

203

data the ecological design needs to be considered. We did not have individual data on receipt

204

of HBV vaccine and it is possible that temporal trends other than the introduction of vaccination

205

may have contributed to the decline in HBV prevalence in Aboriginal women. For example,

206

other known risk factors for HBV infection, such as current or previous injecting drug use and

207

overseas travel to high endemicity countries are not routinely collected in the WA Midwives

208

Notification System and thus we were unable to account for these factors.

209

We demonstrate significant declines in the prevalence of HBV among Aboriginal mothers

210

giving birth for the first time in WA that corresponds with the introduction of targeted

211

vaccination programmes. However, HBV prevalence in Aboriginal mothers remained higher

212

than that of their non-Aboriginal counterparts. Continued screening of pregnant women for

213

HBV and providing babies born to hepatitis B-positive mothers with post-exposure prophylaxis

214

is an important element in prevention of virus transmission. Our cohort consisted of women

215

born between 1974 and 1995 and therefore we were unable to evaluate the impact of the

216

universal newborn vaccination program introduced in May 2000. As these women, born in the

217

universal newborn vaccination era, reach children-bearing age it will be important to continue

218

surveillance to monitor the disparities in HBV prevalence between both Aboriginal and non-

219

Aboriginal women, in Aboriginal women between those resident in regional/remote and cities,

220

and the prevalence of HBV among Australian immigrants. Our findings show that additional

221

efforts are needed to reduce these disparities and these data are vital to inform HBV

222

prevention and treatment programs. Furthermore the methods used here, which are simple

223

and cost effective, could also be used to monitor the impact of vaccination programs in other

224

countries with high HBV prevalence, if antenatal HBV testing is widespread.

225
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238
239

Highlights

240
241

Infant and childhood hepatitis B vaccination programs have been in place in Australia for many

242

years but less is known about their impact on HBV prevalence.

243

A significant decline in HBV prevalence in Aboriginal women was observed following the

244

introduction of HBV vaccination programs in Western Australia.

245

Despite this decline, HBV vaccination programs have not eliminated the considerable

246

disparities in HBV prevalence observed in women according to Aboriginality, ethnicity and

247

area of residence.

248
249
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